Rallybio
Rallybio is a clinical-stage biotechnology company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, and metabolism.
Last updated on
About Rallybio
Founded
2018Estimated Revenue
$10M-$50MEmployees
11-50Funding / Mkt. Cap
$356MCategory
Sector
Health CareIndustry Group
Pharmaceuticals, Biotechnology & Life SciencesIndustry
PharmaceuticalsSIC Code
28NAICs Code
541Location
City
New HavenState
ConnecticutCountry
United StatesRallybio
Find your buyer within Rallybio